Cyfuse Biomedical KK (FSE:4892) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FSE:4892 Cyfuse Biomedical KK FSE:4892
31 GF Score
Price 円527.00
GF Value 円2,172.95
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cyfuse Biomedical KK Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cyfuse Biomedical KK's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

FSE:4892 vs : Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyfuse Biomedical KK Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Cyfuse Biomedical KK's Margin of Safety % (DCF FCF Based) falls into.


FSE:4892
31GF Score
Cyfuse Biomedical KK FSE:4892
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cyfuse Biomedical KK (FSE:4892) Overvalued in 2026?

Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued. The current stock price of 円527.00 is trading 75.7% below its estimated GF Value™ of 円2,172.95. GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.

Key valuation signals for FSE:4892:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: 円2,172.95 vs. price of 円527.00 (75.7% below fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the FSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyfuse Biomedical KK Business Description

Comparable Companies
Address 3-5-27 Mita, 1st Floor, Sumitomo Real Estate Tokyo Mita South Tower, Minato-ku, Tokyo, JPN, 108-6301
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
31GF Score

Get the complete analysis for FSE:4892

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円527.00
Price
円2,172.95
GF Value